Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 51, 2021 - Issue 4
167
Views
1
CrossRef citations to date
0
Altmetric
General Xenobiochemistry

Preliminary in vitro assessment of pharmacokinetic drug-drug interactions of EST64401 and EST64514, two sigma-1 receptor antagonists

, , , , &
Pages 373-386 | Received 17 Nov 2020, Accepted 17 Dec 2020, Published online: 20 Jan 2021

References

  • Bentz, J., et al., 2013. Variability in P-glycoprotein inhibitory potency (IC50) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria. Drug metabolism and disposition: the biological fate of chemicals, 41 (7), 1347–1366.
  • Bjornsson, T.D., et al., 2003. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. Journal of clinical pharmacology, 43 (5), 443–469.
  • Bruna, J., et al., 2018. Efficacy of a novel Sigma-1 receptor antagonist for oxaliplatin-induced neuropathy: a Randomized, double-blind, placebo-controlled phase IIa clinical trial. Neurotherapeutics, 15 (1), 178–189.
  • Bustin, S.A., and Nolan, T., 2004. Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction. Journal of biomolecular techniques, 15 (3), 155–166.
  • Díaz-Fernández, J.L., Almansa-Rosales, C., Cuevas-Cordobés, F. 2014. Tricyclic triazolic compounds as sigma receptors ligands. Patent WO/2014/170494. Available from: https://patentscope.wipo.int/search/es/detail.jsf?docId=WO2014170494 [Accessed 22 Sep 2020].
  • European Medicines Agency (EMA), Committee for medicinal products for human use (CHMP). Draft guideline on the investigation of drug interactions, June 2012. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf [Accessed 22 Sep 2020].
  • Food Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). Draft guidance for industry. In vitro drug interaction studies – cytochrome P450 enzyme- and transporter-mediated drug interactions, January 2020. Available from: https://www.fda.gov/media/134582/download [Accessed 22 Sep 2020].
  • Hu, M., et al., 2004. Use of Caco-2 cell monolayers to study drug absorption and metabolism. In: Z. Yan and G.W. Caldwell, eds. Optimization in drug discovery. In vitro methods. Totowa, NJ: Humana Press, 19–36.
  • Merlos, M., et al., 2017. Pharmacological modulation of the Sigma 1 receptor and the treatment of pain. Advances in experimental medicine and biology, 964, 85–107.
  • Ministry of Labor and Welfare (PMDA). Guideline on drug interaction for drug development and appropriate provision of information, notification No.0723-4, pharmaceutical evaluation division, pharmaceuticals safety and environmental Health bureau, Japan. July 23, 2018. Available from: https://www.pmda.go.jp/files/000228122.pdf [Accessed 22 Sep 2020].
  • Montilla-García, A., et al., 2019. Modulation by sigma-1 receptor of morphine analgesia and tolerance: nociceptive pain, tactile allodynia and grip strength deficits during joint inflammation. Frontiers in pharmacology, 10, 136.
  • Romero, L., et al., 2012. Pharmacological properties of S1RA, a new sigma-1 receptor antagonist that inhibits neuropathic pain and activity-induced spinal sensitization. British journal of pharmacology, 166 (8), 2289–2306.
  • Sanchez-Fernandez, C., et al., 2017. Sigma-1 receptor antagonists: a new class of neuromodulatory analgesics. Advances in experimental medicine and biology, 964, 109–132.
  • Wienkers, L.C., and Heath, T.G., 2005. Predicting in vivo drug interactions from in vitro drug discovery data. Nature reviews. Drug discovery, 4 (10), 825–833.
  • Yan, Z., and Caldwell, G.W., 2001. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery. Current topics in medicinal chemistry, 1 (5), 403–425.
  • Yeste, S., et al., 2020. Preliminary in vitro assessment of the potential of EST64454, a sigma-1 receptor antagonist, for pharmacokinetic drug-drug interactions. Biological & pharmaceutical bulletin, 43 (1), 68–765.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.